MAP2K7 and squamous cell lung carcinoma: for lung squamous cell carcinoma resistant to FGFR1 inhibitors, FGFR1 inhibitor BGJ398 was combined with MEK inhibitor (trametinib) or PI3K inhibitor (BKM120) to overcome the single-drug resistance